Our study demonstrates that the kinase activity of BTK is not essential for oncogenic BCR signaling and suggests that BTK’s noncatalytic function is sufficient to sustain the survival of DLBCL. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.